5-HT_2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.

ABSTRACT: All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D₂ or serotonin (5-HT_2A) receptors, or both; however, these medications are not universally effective, they may produce undesirable side effects, and provide only partial amelioration of negative and cognitive symptoms. The heterogeneity of pharmacological responses in schizophrenic patients suggests that additional drug targets may be effective in improving aspects of this syndrome. Recent evidence suggests that 5-HT_2C receptors may be a promising target for schizophrenia since their activation reduces mesolimbic nigrostriatal dopamine release (which conveys antipsychotic action), they are expressed almost exclusively in CNS, and have weight-loss-promoting capabilities. A difficulty in d

SUBMITTER: Pogorelov VM 

PROVIDER: S-EPMC5603814 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature